Epimedin A1CAS# 140147-77-9 |
| Cas No. | 140147-77-9 | SDF | File under preparation. |
| PubChem ID | 92043273 | Appearance | Yellow crystals |
| Formula | C39H50O20 | M.Wt | 838.8 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Synonyms | Hexandraside F | ||
| Solubility | DMSO : 150 mg/mL (178.83 mM; Need ultrasonic and warming) | ||
| Chemical Name | 3-[(2S,3R,4R,5S,6S)-3,5-dihydroxy-6-methyl-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one | ||
| SMILES | CC1C(C(C(C(O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)OC4C(C(C(C(O4)CO)O)O)O)O)C5=CC=C(C=C5)OC)O)OC6C(C(C(C(O6)CO)O)O)O)O | ||
| Standard InChIKey | NLVBYGTTYRFJKH-YFNAFYFCSA-N | ||
| Standard InChI | InChI=1S/C39H50O20/c1-14(2)5-10-18-20(54-37-30(49)28(47)25(44)21(12-40)55-37)11-19(42)23-27(46)36(33(57-34(18)23)16-6-8-17(52-4)9-7-16)59-39-32(51)35(24(43)15(3)53-39)58-38-31(50)29(48)26(45)22(13-41)56-38/h5-9,11,15,21-22,24-26,28-32,35,37-45,47-51H,10,12-13H2,1-4H3/t15-,21+,22+,24-,25+,26+,28-,29-,30+,31+,32+,35+,37+,38-,39-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Quality Control & MSDS
3D structure
Package In Stock

Number of papers citing our products

| Description | 1. Epimedin A1 has anti-osteoporosis activity. |
Epimedin A1 Dilution Calculator
Epimedin A1 Molarity Calculator
-
Epimedin ACatalog No.: BCN1038CAS No.: 110623-72-8 -
Epimedin CCatalog No.: BCN1040CAS No.: 110642-44-9 -
Baohuoside VICatalog No.: BCC8129CAS No.: 119760-73-5 -
Maohuoside BCatalog No.: BCN8084CAS No.: 849834-04-4 -
IcariinCatalog No.: BCN6311CAS No.: 489-32-7 -
Epimedin ICatalog No.: BCX0752CAS No.: 205445-00-7 -
Caohuoside ECatalog No.: BCN8198CAS No.: 174286-23-8 -
Baohuoside VIICatalog No.: BCN2889CAS No.: 119730-89-1 -
Sagittatoside ACatalog No.: BCN2285CAS No.: 118525-35-2 -
Epimedin BCatalog No.: BCN1039CAS No.: 110623-73-9 -
Epimedin B1Catalog No.: BCN8199CAS No.: 133137-58-3 -
Baohuoside VCatalog No.: BCN2887CAS No.: 118544-18-6 -
Sagittatoside CCatalog No.: BCN3059CAS No.: 118525-37-4 -
Epimedoside ACatalog No.: BCN2886CAS No.: 39012-04-9 -
Epimedin KCatalog No.: BCN8201CAS No.: 174286-13-6 -
Icariside ICatalog No.: BCN3463CAS No.: 56725-99-6 -
2''-O-Rhamnosylicariside IICatalog No.: BCN3464CAS No.: 135293-13-9 -
Baohuoside ICatalog No.: BCN5350CAS No.: 113558-15-9 -
Korepimedoside ACatalog No.: BCN7887CAS No.: 106441-31-0 -
Sagittatoside BCatalog No.: BCN2357CAS No.: 118525-36-3 -
Rhodiosin; Herbacetin-7-O-glucorhamnosideCatalog No.: BCN8478CAS No.: 86831-54-1 -
Baohuoside IICatalog No.: BCN2888CAS No.: 55395-07-8
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.1922 mL | 5.9609 mL | 11.9218 mL | 23.8436 mL | 29.8045 mL |
| 5 mM | 0.2384 mL | 1.1922 mL | 2.3844 mL | 4.7687 mL | 5.9609 mL |
| 10 mM | 0.1192 mL | 0.5961 mL | 1.1922 mL | 2.3844 mL | 2.9804 mL |
| 50 mM | 0.0238 mL | 0.1192 mL | 0.2384 mL | 0.4769 mL | 0.5961 mL |
| 100 mM | 0.0119 mL | 0.0596 mL | 0.1192 mL | 0.2384 mL | 0.298 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
- Pterisolic acid F
Catalog No.:BCN4840
CAS No.:1401419-90-6
- Pterisolic acid E
Catalog No.:BCN4841
CAS No.:1401419-89-3
- Pterisolic acid D
Catalog No.:BCN4839
CAS No.:1401419-88-2
- Pterisolic acid C
Catalog No.:BCN4838
CAS No.:1401419-87-1
- Pterisolic acid B
Catalog No.:BCN4843
CAS No.:1401419-86-0
- Pterisolic acid A
Catalog No.:BCN4842
CAS No.:1401419-85-9
- 15,16-Dihydroxyoctadeca-9Z,12Z-dienoic acid
Catalog No.:BCC8438
CAS No.:140129-22-2
- ML 277
Catalog No.:BCC7976
CAS No.:1401242-74-7
- PI-1840
Catalog No.:BCC5453
CAS No.:1401223-22-0
- 3'-Hydroxygynuramide II
Catalog No.:BCC8634
CAS No.:1401093-57-9
- AMG 925
Catalog No.:BCC5150
CAS No.:1401033-86-0
- Tannic acid
Catalog No.:BCN2643
CAS No.:1401-55-4
- ATPA
Catalog No.:BCC6940
CAS No.:140158-50-5
- Negundonorin A
Catalog No.:BCN7150
CAS No.:1401618-51-6
- (-)-Praeruptorin A
Catalog No.:BCN7664
CAS No.:14017-71-1
- Monnieriside G
Catalog No.:BCN7857
CAS No.:1401799-34-5
- Monnieriside A
Catalog No.:BCN7892
CAS No.:1401807-73-5
- (S)-(-)-5-Fluorowillardiine
Catalog No.:BCC6596
CAS No.:140187-23-1
- (S)-(-)-5-Iodowillardiine
Catalog No.:BCC6597
CAS No.:140187-25-3
- Mc-MMAD
Catalog No.:BCC1735
CAS No.:1401963-15-2
- Vc-MMAD
Catalog No.:BCC2032
CAS No.:1401963-17-4
- GSK2879552
Catalog No.:BCC6422
CAS No.:1401966-69-5
- Psiguadial D
Catalog No.:BCN7086
CAS No.:1402066-95-8
- Eupalinolide I
Catalog No.:BCN7367
CAS No.:1402067-84-8
[Determination of flavonoids constituents in epimedium total flavone capsule and research on its anti-osteoporosis activity].[Pubmed:30200709]
Zhongguo Zhong Yao Za Zhi. 2018 Aug;43(15):3140-3144.
To develop a rapid resolution liquid chromatography (RRLC) method for the simultaneous determination of epimedoside A, Epimedin A1, epimedin A, epimedin B, epimedin C, icariin, baohuoside, icariside, sagittatoside B, 2"-O-rhamnosyl icariside, and baohuosidein epimedium total flavone capsule. At the same time, the effects of the above 11 compounds on osteogenic differentiation of MC3T3-E1 cells were investigated by detecting the content of alkaline phosphatase (AKP). The results showed that baohuoside had the highest activities, and both the activities of baohuoside and icariside were stronger than those of icariin.In this study, the content determination method of flavonoid glycosides was established, and the anti-osteoporosis effect of monomers was compared, providing technical support for the study of the pharmacodynamic and mechanism of Epimedium total flavone capsule.
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University


